drugset / Trial / NCT01997411

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

NCT01997411

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given nasally was evaluated.

Timeline

Start
2013-11
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide 0.5 mg Intranasal
Subject Glucagon Peptide 1 mg Intranasal
Subject Glucagon Peptide 2 mg Intranasal
Subject Glucagon Peptide 3 mg Intranasal